Trial Profile
A Phase 1 Study of PXD101 in Combination With Bortezomib (PS-341) in Patients With Advanced Solid Tumors and Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Belinostat (Primary) ; Bortezomib (Primary)
- Indications Anaplastic large cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoid leukaemia; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 19 Apr 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 26 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Nov 2009 Data from 22 patients were presented at the AACR/NCI/EORTC Molecular Targets and Cancer Therapeutics Conference 2009, according to a Topotarget media release. To date, 26 patients have been enrolled.